Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Veracyte Inc Logo

ARKG Holdings of Veracyte (VCYT) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
September 20, 2022
BUY329.682k0.2318%ARKG
September 19, 2022
BUY20.446k0.014%ARKG
September 14, 2022
BUY117.290k0.0834%ARKG
September 13, 2022
BUY200.859k0.1349%ARKG
January 20, 2022
BUY26.000k0.0185%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKWARKG$18.49
⚖️Weighting🧢Market Cap
1.78%$1.32b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
214.93
🏋️‍♀️Weight Rank Across All Funds🌏Country
25🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$18.523.4%
Description
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Website
www.veracyte.com